HER2 Vaccine for Locally Advanced Breast Cancer
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864 3. Histologically confirmed HER2 positive breast cancer 1. Any Estrogen Receptor/Progesterone Receptor status is allowed. 2. HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \> 2.0 or \> 6 total HER2 gene copies per cell. 4. High-risk disease defined as one of the following: 1. Any residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant taxane and trastuzumab-based chemotherapy 2. Inflammatory phenotype at the time of diagnosis per the treating physician 3. Clinical stage III disease at the time of diagnosis per the treating physician and/or clinical imaging 4. Locally recurrent disease and have undergone definitive local therapy 5. Received at least six months of HER